Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people
- PMID: 31787585
- DOI: 10.1016/S2215-0366(19)30414-6
Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4 717 839 people
Erratum in
-
Correction to Lancet Psychiatry 2019; published online Nov 28. https://doi.org/10.1016/S2215-0366(19)30414-6.Lancet Psychiatry. 2020 Jan;7(1):e3. doi: 10.1016/S2215-0366(19)30472-9. Epub 2019 Dec 4. Lancet Psychiatry. 2020. PMID: 31812366 No abstract available.
Abstract
Background: Since people with mental illness are more likely to die from cancer, we assessed whether people with mental illness undergo less cancer screening compared with the general population.
Methods: In this systematic review and meta-analysis, we searched PubMed and PsycINFO, without a language restriction, and hand-searched the reference lists of included studies and previous reviews for observational studies from database inception until May 5, 2019. We included all published studies focusing on any type of cancer screening in patients with mental illness; and studies that reported prevalence of cancer screening in patients, or comparative measures between patients and the general population. The primary outcome was odds ratio (OR) of cancer screening in people with mental illness versus the general population. The Newcastle-Ottawa Scale was used to assess study quality and I2 to assess study heterogeneity. This study is registered with PROSPERO, CRD42018114781.
Findings: 47 publications provided data from 46 samples including 4 717 839 individuals (501 559 patients with mental illness, and 4 216 280 controls), of whom 69·85% were women, for screening for breast cancer (k=35; 296 699 individuals with mental illness, 1 023 288 in the general population), cervical cancer (k=29; 295 688 with mental illness, 3 540 408 in general population), colorectal cancer (k=12; 153 283 with mental illness, 2 228 966 in general population), lung and gastric cancer (both k=1; 420 with mental illness, none in general population), ovarian cancer (k=1; 37 with mental illness, none in general population), and prostate cancer (k=6; 52 803 with mental illness, 2 038 916 in general population). Median quality of the included studies was high at 7 (IQR 6-8). Screening was significantly less frequent in people with any mental disease compared with the general population for any cancer (k=37; OR 0·76 [95% CI 0·72-0·79]; I2=98·53% with publication bias of Egger's p value=0·025), breast cancer (k=27; 0·65 [0·60-0·71]; I2=97·58% and no publication bias), cervical cancer (k=23; 0·89 [0·84-0·95]; I2=98·47% and no publication bias), and prostate cancer (k=4; 0·78 [0·70-0·86]; I2=79·68% and no publication bias), but not for colorectal cancer (k=8; 1·02 [0·90-1·15]; I2=97·84% and no publication bias).
Interpretation: Despite the increased mortality from cancer in people with mental illness, this population receives less cancer screening compared with that of the general population. Specific approaches should be developed to assist people with mental illness to undergo appropriate cancer screening, especially women with schizophrenia.
Funding: None.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Comment in
-
Reducing global disparities in cancer screening for people with mental illness.Lancet Psychiatry. 2020 Jan;7(1):4-6. doi: 10.1016/S2215-0366(19)30470-5. Epub 2019 Nov 29. Lancet Psychiatry. 2020. PMID: 31787584 Free PMC article. No abstract available.
Similar articles
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Colorectal, cervical and prostate cancer screening in Australians with severe mental illness: Retrospective nation-wide cohort study.Aust N Z J Psychiatry. 2019 Jun;53(6):550-558. doi: 10.1177/0004867418814945. Epub 2018 Dec 2. Aust N Z J Psychiatry. 2019. PMID: 30501394
-
Cancer Screening Among Adults With and Without Serious Mental Illness: A Mixed Methods Study.Med Care. 2021 Apr 1;59(4):327-333. doi: 10.1097/MLR.0000000000001499. Med Care. 2021. PMID: 33704103 Free PMC article.
-
Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies.Am J Psychiatry. 2021 Sep 1;178(9):793-803. doi: 10.1176/appi.ajp.2021.21010031. Epub 2021 Jul 14. Am J Psychiatry. 2021. PMID: 34256605
-
Breast, Cervical, and Colorectal Cancer Screening Adherence: Effect of Low Body Mass Index in Women.J Womens Health (Larchmt). 2020 Jul;29(7):996-1006. doi: 10.1089/jwh.2019.7739. Epub 2020 Jan 10. J Womens Health (Larchmt). 2020. PMID: 31928405
Cited by
-
Prediction of medical admissions after psychiatric inpatient hospitalization in bipolar disorder: a retrospective cohort study.Front Psychiatry. 2024 Sep 3;15:1435199. doi: 10.3389/fpsyt.2024.1435199. eCollection 2024. Front Psychiatry. 2024. PMID: 39290307 Free PMC article.
-
The Risk and The Course of Cancer Among People with Severe Mental Illness.Clin Pract Epidemiol Ment Health. 2023 Dec 3;19(Suppl-1):e174501792301032. doi: 10.2174/17450179-v17-e211208-2021-HT2-1910-8. eCollection 2023. Clin Pract Epidemiol Ment Health. 2023. PMID: 38659632 Free PMC article. Review.
-
Epidemiological and Genetic Analyses of Schizophrenia and Breast Cancer.Schizophr Bull. 2024 Mar 7;50(2):317-326. doi: 10.1093/schbul/sbad106. Schizophr Bull. 2024. PMID: 37467357 Free PMC article.
-
Recommandations pour des soins préventifs pour promouvoir l’équité en matière de santé.CMAJ. 2023 Dec 10;195(48):E1674-E1701. doi: 10.1503/cmaj.230237-f. CMAJ. 2023. PMID: 38081626 Free PMC article. French.
-
Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment.Mol Cancer. 2025 Jan 17;24(1):24. doi: 10.1186/s12943-024-02219-0. Mol Cancer. 2025. PMID: 39825376 Free PMC article. Review.